17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells
Yu Zuo,Heng Xu,Zhifeng Chen,Fengmin Xiong,Bei Zhang,Kaixian Chen,Hualiang Jiang,Cheng Luo,Hao Zhang +8 more
Reads0
Chats0
TLDR
The synergistic effect of the heat shock protein 90 inhibitor 17-AAG and the histone deacetylase 6 inhibitor Belinostat in triple-negative breast cancer MDA-MB-231 cells is reported, by detection of proliferation, apoptosis and cell cycle arrest following treatment with this combination.Abstract:
Breast cancer is one of the most common malignancies that threaten the health of women. Although there are a few chemotherapies for the clinical treatment of breast cancer, these therapies are faced with the problems of drug‑resistance and metastasis. Drug combination can help to reduce the adverse side effects of chemotherapies using single drugs, and also help to overcome common drug‑resistance during clinical treatment of breast cancer. The present study reported the synergistic effect of the heat shock protein 90 inhibitor 17‑AAG and the histone deacetylase 6 inhibitor Belinostat in triple‑negative breast cancer (TNBC) MDA‑MB‑231 cells, by detection of proliferation, apoptosis and cell cycle arrest following treatment with this combination. Subsequently, RNA sequencing (RNA‑seq) data was collected and analyzed to investigate the synergistic mechanism of this combination. Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways revealed by RNA‑seq data analysis, a wound‑healing assay was used to investigate the effect of this combination on the migration of MDA‑MB‑231 cells. Compared with treatment with 17‑AAG or Belinostat alone, both the viability inhibition and apoptosis rate of MDA‑MB‑231 cells were significantly enhanced in the combination group. The combination index values were <1 in three concentration groups. Revealed by the RNA‑seq data analysis, the most significantly enriched KEGG pathways in the combination group were closely associated with cell migration. Based on these findings, the anti‑migration effect of this combination was investigated. It was revealed that the migration of MDA‑MB‑231 cells was significantly suppressed in the combination group compared with in the groups treated with 17‑AAG or Belinostat alone. In terms of specific genes, the mRNA expression levels of TEA domain family proteins were significantly decreased in the combination group, whereas the phosphorylation of YY1 associated protein 1 and modulator of VRAC current 1 was significantly enhanced in the combination group. These alterations may help to explain the anti‑migration effect of this combination. Belinostat has already been approved as a treatment for T‑cell lymphoma and 17‑AAG is undergoing clinical trials. These findings could provide a beneficial reference for the clinical treatment of patients with TNBC.read more
Citations
More filters
Journal ArticleDOI
Recent treatment progress of triple negative breast cancer.
Yang Chang-Qing,Liu Jie,Zhao Shi-Qi,Zhu Kun,Gong Zi-Qian,Xu Ran,Lu Hui-Meng,Zhou Ren-Bin,Zhao Gang,Yin Dachuan,Zhang Chen-Yan +10 more
TL;DR: The classification of TNBC, its molecular mechanisms of pathogenesis, treatment methods and prognosis are reviewed and some new treatment methods have been proposed in recent years, such as nutritional therapy and noncoding RNA treatment methods.
Journal ArticleDOI
Vorinostat (SAHA) and Breast Cancer: An Overview.
TL;DR: Vorinostat (SAHA) is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006.
Journal ArticleDOI
Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way.
TL;DR: In this article, a review summarizes the existing evidence regarding HMs that are involved in BC and the potential mechanisms that are related to aberrant HMs, and examines the currently available agents and approved drugs that have been tested in pre-clinical and clinical studies to evaluate their effects on HMs.
Journal ArticleDOI
Computationally repurposing drugs for breast cancer subtypes using a network-based approach
TL;DR: In this article , a network-based integration approach was proposed to best capture knowledge (and complex relationships) contained within and between drugs, genes and disease data, which was applied thereafter by using the extracted knowledge and relationships in order to identify single and pair of approved or experimental drugs with potential therapeutic effects on different breast cancer subtypes.
References
More filters
Journal ArticleDOI
Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method
TL;DR: The 2-Delta Delta C(T) method as mentioned in this paper was proposed to analyze the relative changes in gene expression from real-time quantitative PCR experiments, and it has been shown to be useful in the analysis of realtime, quantitative PCR data.
Journal ArticleDOI
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
Daehwan Kim,Daehwan Kim,Geo Pertea,Cole Trapnell,Cole Trapnell,Harold Pimentel,Kelley Ryan Matthew,Steven L. Salzberg,Steven L. Salzberg +8 more
TL;DR: TopHat2 is described, which incorporates many significant enhancements to TopHat, and combines the ability to identify novel splice sites with direct mapping to known transcripts, producing sensitive and accurate alignments, even for highly repetitive genomes or in the presence of pseudogenes.
Journal ArticleDOI
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Cole Trapnell,Adam Roberts,Loyal A. Goff,Loyal A. Goff,Loyal A. Goff,Geo Pertea,Daehwan Kim,Daehwan Kim,David R. Kelley,David R. Kelley,Harold Pimentel,Steven L. Salzberg,John L. Rinn,John L. Rinn,Lior Pachter +14 more
TL;DR: This protocol begins with raw sequencing reads and produces a transcriptome assembly, lists of differentially expressed and regulated genes and transcripts, and publication-quality visualizations of analysis results, which takes less than 1 d of computer time for typical experiments and ∼1 h of hands-on time.
Journal ArticleDOI
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
TL;DR: The median-effect principle and its mass-action law based computer software are gaining increased applications in biomedical sciences, from how to effectively evaluate a single compound or entity to how to beneficially use multiple drugs or modalities in combination therapies.
Journal ArticleDOI
Differential analysis of gene regulation at transcript resolution with RNA-seq
Cole Trapnell,David G. Hendrickson,David G. Hendrickson,Martin Sauvageau,Martin Sauvageau,Loyal A. Goff,Loyal A. Goff,John L. Rinn,John L. Rinn,Lior Pachter +9 more
TL;DR: Cuffdiff 2, an algorithm that estimates expression at transcript-level resolution and controls for variability evident across replicate libraries, robustly identifies differentially expressed transcripts and genes and reveals differential splicing and promoter-preference changes.